ITGAL: Integrin alpha-L
Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on ITGAL, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Odulimomab | Phase 3 | — | Antibody | InhibitorLeukocyte adhesion glycoprotein LFA-1 alpha inhibitor | 0 |
- Psoriasis vulgaris0.58
- Dry eye syndrome0.57
- Psoriasis0.47
- Eye disorder0.37
- Ulcerative colitis0.34
- Atopic conjunctivitis0.26
- Inflammatory bowel disease0.25
- Chronic obstructive pulmonary disease0.22
- Gastroesophageal reflux disease0.21
- Neoplasm0.12
- Type 1 diabetes mellitus0.11
- Myoepithelial tumor0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1803, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P20701, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets